[The transformation of acute viral hepatitis B into chronic].
Sorinson. S N SN; Korochkina. O V OV; Frolov. A V AV; Shamshura. O L OL; Fomin. E A EA; Kuzovatova. E E EE; Neumoina. M V MV; Zhdanov. Iu E IuE; Sivukhina. N I NI
Key Findings
- Mild disease, progressive course, and poor immune response raise chronic hepatitis B risk
- Dynamic HBeAg/anti‑HBe monitoring predicts chronic infection type
- Early interferon plus thymogen treatment may prevent chronic transformation
Practical Outcomes
- If you get acute hepatitis B, starting interferon therapy combined with thymogen quickly could lower the chance of the infection turning chronic. This approach requires medical supervision and isn’t a general anti‑aging protocol, so its use is limited to specific viral infections.
Summary
The study followed 500 hepatitis B patients and found that people with a mild form of the disease, a worsening course, or weak immune response are more likely to develop chronic hepatitis. Tracking specific blood markers (HBeAg and anti‑HBe) helps predict whether the virus will become a long‑term problem. Giving interferon (reaferon) together with the peptide thymogen early on may stop the infection from becoming chronic in many cases.
Abstract
500 patients with hepatitis B have been followed up from the acute onset to long-term outcome. As for chronic transformation of the disease, at higher risk are patients with mild form, progredient run and inadequate immune response. Of the highest value for identification and prognostication was a dynamic quantitative control over the system HBeAg-anti-HBe providing separate prognosis of establishment of replicative or integrative variants of chronic hepatitis B. In progredient infection an early administration of reaferon in combination with thymogen is thought valid which in many patients is sufficient to prevent the disease transformation into a chronic form.
Study Information
pubmed
1996